Over the past few decades, the mainstay of hypertension management has been pharmacological therapy; however, there is now a growing body of evidence that drug-resistant hypertension can be managed effectively by renal artery ablation. Several studies have documented the feasibility and safety of this treatment, although data regarding long-term outcomes are still emerging. Atrial fibrillation (AF) and hypertension commonly coexist, and recent work has demonstrated improved outcomes from catheter ablation of AF with concomitant renal artery denervation at little extra cost in terms of time and resource. The aim of this review is to explore the link between hypertension and AF, the synergistic effect of renal artery ablation on AF ablation, explain how this may work and address unanswered questions.
INTRODUCTION
Hypertension is one of the most prevalent conditions of the developed world and one of the primary risk factors for cardiovascular disease; the leading cause of death worldwide. 1, 2 At the turn of the century, it was estimated to affect just over a quarter of the world's adult population, a figure expected to rise to nearly a third by 2025. 3 Atrial fibrillation (AF) is the most common cardiac arrhythmia, and a major cause of morbidity and burden to health-care systems. [4] [5] [6] With the ageing population, epidemiological studies project that AF will be rising to epidemic levels by 2050. 7 Hypertension is a well-established risk factor for the development of AF, with as many as 50-70% patients with AF having coexisting hypertension, [8] [9] [10] [11] [12] with rhythm control being more challenging in patients with AF and hypertension. 13 The incidence of drug-resistant hypertension (defined as blood pressure above target despite three antihypertensive agents including a diuretic) is rising and it currently affects 8-12% of the adult hypertensive population in the United States. 14 The mainstay of AF and hypertension control to date has been drug therapy. Over the past decade, catheter ablation for AF has emerged as a valuable treatment in patients with drug-refractory AF. 15 More recently, renal artery ablation has shown promise in the management of patients with severe hypertension not controlled by medical therapy. 16 In 2012, Pokushalov et al. 17 demonstrated improved outcomes in patients with AF and severe hypertension undergoing catheter ablation of AF and renal artery ablation during the same procedure. As AF and hypertension are so intimately linked, then can the indication for combined AF ablation and renal artery ablation be a new target for therapy in these often challenging to treat patients? This review will outline the relationship between hypertension and AF while exploring the increasing body of evidence suggesting that additional hypertension control with renal artery ablation (with the intention of denervation) may offer a new target in the management of this important condition.
SEARCH STRATEGY
For the purposes of this review, a systematic literature search was performed using MEDLINE and EMBASE from 1996 until May 2013, with one or more combinations of the following terms: atrial fibrillation, hypertension, renal artery ablation, renal artery denervation and atrial fibrillation ablation. Additional specific large-scale studies/trials that met some but not all of the above criteria but were deemed relevant to this article were also included.
PREVENTION OF AF IN PATIENTS WITH HYPERTENSION
Several large-scale studies have investigated whether a reduction in arterial blood pressure (BP) prevents the development of AF in patients with hypertension. 15 It has also been of interest whether certain antihypertensive agents have additional mechanisms of action in the prevention of AF in addition to BP lowering per se (Table 1) . It has been hypothesised that angiotensinconverting enzyme (ACE) inhibitors and angiotensin receptor blockers may have an additional role in preventing AF by preventing renin-angiotensin system (RAS)-mediated electrical and structural atrial remodelling. 18 Although the data are conflicting, the conclusions are robust enough for ACE inhibitors to be a class IIa recommendation in the European Society of Cardiology (ESC) 2010 guidelines for prevention of new-onset AF in patients with hypertension, particularly with left ventricular hypertrophy. 15 Although AF in patients with structural heart disease tends to be adrenergically driven, 19 there are no data to suggest that b-blocker therapy has any benefit over other antihypertensive regimes in the primary prevention of AF in the absence of systolic heart failure. Although more data are required in vivo, several animal models have suggested that aldosterone antagonists may be beneficial in primary prevention of AF.
SECONDARY PREVENTION OF AF IN PATIENTS WITH HYPERTENSION
Unlike in primary prevention, there is no tangible evidence that RAS blockers as sole agents are helpful in prevention of recurrence of AF following direct-current cardioversion or radiofrequency ablation. 21, 22 There does, however, appear to be some benefit in RAS blockade in combination with amiodarone in maintenance of sinus rhythm following direct-current cardioversion and this effect could be dependent on the dose of the RAS blocker. 23 Data from a small-scale prospective, randomised trial suggests that the use of spironolactone in addition to a b-blocker ± ACE inhibitor significantly reduces the number of symptomatic AF episodes in patients with paroxysmal or persistent AF. Interestingly these patients had normal left ventricular function. 24 Unfortunately, secondary prevention studies included a heterogeneous group of patients in which hypertension was not always a prerequisite for recruitment (Table 2) . CTAF-2 (Canadian Trial on Atrial Fibrillation-2), a prospective double-blind, placebo-controlled study looking at the effect of ACE inhibitor perindopril in patients with AF and hypertension, will be the first adequately powered prospective trial to date to look at the role of ACE inhibitors in prevention of AF following direct-current cardioversion in patients with hypertension. 25 Therefore, currently, there is no strong evidence that the treatment of hypertension affects AF control. However, there are data to suggest that the two conditions are intimately linked. For example, in the Framingham cohort, increased systolic BP and duration of hypertension was directly related to adverse atrial remodelling. 26 Furthermore, left atrial size and left ventricular mass have both been shown to be predictors of AF in patients with hypertension. 4, 27 HYPERTENSION AND AF Left ventricular hypertrophy is often the end product of longstanding hypertension. 1 Initially, this manifests as a reduction in left ventricular compliance that in turn leads to an elevation in left atrial pressure, increased left atrial size and reduced atrial function as a result of atrial remodelling. 28, 29 The development of AF in the patient with hypertension is complex and its mechanism is not entirely understood, although it is at least in part thought to relate to structural changes within the atria. Atrial remodelling can be subclassified into several categories: structural, electrical, neurohormonal and metabolic. 30 Structural left atrial remodelling, which is manifest by chamber dilatation and interstitial fibrosis, can be reversible, especially if measures are taken early in the course of the pathological process. 31 Increased fibrosis and scarring are potential substrates for re-entry circuits. 32 Moreover, cardiac myocytes are more readily depolarised in the presence of elevated left atrial pressure and volume. 30 Left atrial remodelling results in various neurohormonal disturbances including increases in circulating levels of atrial natriuretic peptide, brain natriuretic peptide, angiotensin II and aldosterone, among others. 30 Angiotensin II is a powerful vasoconstrictor that plays a key role in the promotion of interstitial fibrosis via protein kinase activation. 33 The development of AF further perpetuates a vicious cycle of negative structural and electrical remodelling. 34 It is therefore disappointing that medical therapy of hypertension, which has a major impact on the development of AF, does so little to control AF. The reason for this remains unclear but could perhaps be related to the relatively modest drop in BP, patient compliance and lack of impact on central regulation of BP.
CATHETER ABLATION OF AF
Catheter ablation is conventionally considered as a second-line therapy for AF in patients who remain symptomatic despite optimal medical therapy. 35 Data from numerous trials demonstrate its superiority to antiarrhythmic medication alone, with a real-world meta-analysis suggesting a major complication risk of 4.5%, 36 including cerebral thromboembolism, pulmonary vein stenosis, cardiac tamponade and access site haematoma. The best outcome data are in those with paroxysmal AF where success rates (defined as AF free at 12 months) are reported between 75 and 83%. 36 In patients with persistent AF, multiple attempts at ablation are often required with a less favourable outcome (65-75%).
Catheter ablation of AF is mostly performed percutaneously via the femoral vein using local anaesthesia with conscious sedation or alternatively under general anaesthetic. The atrial septum is crossed using a transseptal puncture allowing access into the left atrium.
Most AF is triggered by ectopic foci originating in the pulmonary vein sleeve, and therefore pulmonary vein isolation (PVI) is the cornerstone of AF ablation. The left atrium can be mapped using a three-dimensional mapping system, or the procedure can be done using fluoroscopy only. There are two Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; BB, b-blocker; CCB, calcium channel blocker; CI, confidence interval; ECG, electrocardiography; HR, hazard ratio; HTN, hypertension; LVH, left ventricular hypertrophy; RCT, randomised control trial.
Simultaneous ablation of atrial fibrillation and renal arteries AJ Hogarth et al commonly used mapping systems: an electromagnetic system (CARTO, Biosense-Webster, Diamond Bar, CA, USA) where a magnetic coil mounted under the patient table emits a magnetic field that communicates with a sensor in the catheter tip, and the Ensite Nav-X system (St Jude Medical, Inc., Minneapolis, MN, USA) that is based on a measure of the voltage gradient measured at the catheter tip with reference to three pairs of surface electrodes placed on the patient's skin and a reference electrode. PVI is the cornerstone of AF ablation. This is either performed by ipsilateral pulmonary vein antral or ostial ablation using a deflectable radiofrequency ablation catheter to create point-by-point lesions, balloon based (for example, cryoablation or laser) or circular multipolar radiofrequency ablation catheters. 37 In patients with persistent AF, additional strategies can be added aimed at substrate modification such as additional ablation lines in the left atrium itself or targeting sites with complex atrial fractionated electrograms. 38 Electrical isolation is subsequently confirmed using a mapping catheter at the pulmonary vein ostium. The demonstration of bidirectional block translates to the best outcomes; studies have shown increased AF recurrence rates when there is incomplete electrical isolation. 39 The outcome of AF ablation is worse in patients with hypertension. 40 
CATHETER ABLATION OF RENAL ARTERY SYMPATHETIC NERVES
Renal artery ablation is a relatively new concept in the management of drug-resistant hypertension. Afferent and efferent renal nerves within the wall of the renal artery are anatomically positioned such that over 90% are within a depth of 2 mm. 41 A typical ablation lesion in the heart would expect to achieve a depth of 5-7 mm when using a standard (4 mm) ablation catheter tip. 42 It therefore follows that radiofrequency ablation of the renal artery could affect the functioning of these nerves (see Figure 1 ) that play a pivotal role in the neurohormonal control of BP including the involvement of the sympathetic nervous system. The response of the kidneys to sympathetic nervous system output plays an important role in mediating the relationship between sympathetic activation and increasing BP. 40, 43 Renal sympathetic stimulation increases renin secretion, reduces urinary sodium and increases renal vasoconstriction. Therefore, targeting efferent sympathetic and sensory afferent renal nerves with ablation could affect the regulation of BP by reducing central sympathetic drive. 43 Thermal destruction of renal arterial myocytes could attenuate the vasoconstrictor capability of the renal artery also potentially affecting BP control. All patients undergoing catheter ablation for paroxysmal or permanent AF (35% HTN).
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No effect of RAAS modulation on AF recurrence rates.
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BB, b-blocker; CCB, calcium channel blocker; DC, direct current; HTN, hypertension; LVH, left ventricular hypertrophy; NS, not significant; RAAS, renin-angiotensin-aldosterone system; RCT, randomised control trial; SR, sinus rhythm.
Simultaneous ablation of atrial fibrillation and renal arteries AJ Hogarth et al
In 2009, a proof-of-principle trial was published, 16 with the subsequent publication in 2010 of a multicentre, prospective, randomised trial: Symplicity HTN-2. 44 Data from these studies showed that a substantial reduction in BP could be achieved safely by renal artery ablation (Table 3 ). The technique is described briefly here; femoral arterial access is obtained and a guide catheter is inserted under fluoroscopic guidance into each renal artery in turn. The arteries are then ablated using radiofrequency energy at discrete circumferential points (separated longitudinally) in both renal arteries from the renal end to the ostium. Most of the trial data to date have been obtained using the Symplicity catheter (Ardian Inc., Palo Alto, CA, USA). A method using the same ablation catheters and three-dimensional mapping systems as those used in AF ablation has also recently been described, with the use of high-frequency stimulation to confirm renal denervation. 17 The procedure is considered as relatively low in complexity for practitioners experienced in techniques of catheter ablation and is well tolerated by the patient under light sedation. Complications reported to date include guide catheter dissection of the renal artery and access site pseudoaneurysm. Concern regarding the potential for renal artery stenosis has not been reflected by any reported incidence in the patients studied and Figure 1 . Schematic representation of the effects of sympathetic nerve activation (SNA) and its role in perpetuating atrial fibrillation (AF) and hypertension. The influence on vascular endothelial remodelling and cardiac remodelling, and the changes in electrical, structural, autonomic and metabolic remodelling of the heart increase the likelihood of developing atrial arrhythmia. Abbreviations: BP, blood pressure; HTN, hypertension; RCT, randomised control trial.
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Simultaneous ablation of atrial fibrillation and renal arteries AJ Hogarth et al followed up for over 6 months with duplex ultrasound scanning, computed tomography angiography or renal artery magnetic resonance imaging; 44 however, follow-up to date is short term and long-term safety and outcome data are still required. 45 The reduction in BP seems to not only sustain over time, with data now extending to 18 months in Symplicity HTN-2 46 and 2 years in its nonrandomised predecessor Symplicity HTN-1, 47 but also to increase, facilitating a reduction in pharmaceutical therapy. The initial BP reduction is more modest, progressing over the first 6 months. The mechanisms relating to this slow and steady reduction in BP are the focus of much investigation. They are hitherto unheralded, potentially representing a beneficial and persistent resetting of neurohormonal reflex activity that may offer multisystem benefits in promoting cardiovascular risk reduction far beyond that of BP moderation alone, including left ventricular hypertrophy, 48 cardiac dysfunction 49, 50 and the cardiac remodelling that promotes atrial arrhythmia. 17 Despite initial optimism and enthusiasm regarding this novel therapy, some questions remain, specifically with regard to issues of patient selection in the trials conducted so far, and the nature of medical therapy in those included: Will this strategy be effective in those not needing multiple drug therapy, with more modest forms of hypertension? Will the BP reduction sustain and facilitate reduction in drug therapy? Can patients with commonly coexistent pathology such as cardiac failure and chronic kidney disease be safely and effectively treated with this approach? 51 
THE INTERACTION BETWEEN THE RENAL ARTERIES AND AF
Hypertension is a strong predictor of arrhythmia recurrence following PVI with catheter ablation. 13 Given that hypertension control can be improved following ablation of the renal arteries, and that the BP reduction is far superior to that of current medical therapy, the question arises of whether the outcomes of AF can be improved with concomitant ablation of the renal arteries. In order to investigate this further, Pokushalov et al.
17
prospectively analysed 27 patients with drug-resistant hypertension undergoing catheter ablation for AF. Fourteen patients were randomised to PVI alone and 13 to PVI plus renal artery ablation. Nine persistent AF patients were included in each arm. Despite the small sample size, the authors were able to demonstrate a large and significant increase in freedom from AF at 12 months in the renal ablation group (69% vs 29%, P ¼ 0.033). There was also a significant reduction in systolic (from 181.7 to 156.5 mm Hg, Po0.001) and diastolic BP (from 97.6 to 87.4 mm Hg, Po0.001) as well as a reduction in left ventricular mass in the renal ablation arm. As expected, the procedure took longer in the renal ablation patients (mean 192±36 min vs 154±28 min), with a nonsignificant increase in mean fluoroscopy times (29±14 vs 21 ± 16 min).
There are animal data to suggest that renal artery ablation alone can reduce both ventricular rate in AF 52 and time spent in AF after induction. 52, 53 Furthermore, animal models of obstructive sleep apnoea have shown positive effects after ablation of the renal arteries with regard to reduction in shortening of the atrial refractory period and postobstructive BP rises associated with obstructive apnoeic events, 52 suggesting a higher threshold for atrial arrhythmia following renal artery ablation.
MECHANISTIC HYPOTHESES
Although questions have been asked over the dismal success rates of AF ablation in the control group, these single-centre results cannot be ignored. 51 When considering explanation of these findings, important implications regarding the multisystem effects of renal artery ablation in the context of AF ablation should be discussed. First, it is necessary to review the physiological relationship between sympathetic activity and hypertension.
The physiological relationship between sympathetic activation and hypertension Arterial BP is determined during the steady state by cardiac output and total peripheral resistance. 54 Cardiac output is determined by stroke volume and heart rate. The former is controlled by left ventricular filling and size (involving venous return and the Starling Law) and left ventricular inotropic changes (involving the sympathetic drive, hormonal and biochemical factors). The role of heart rate is complex, in that an increase would in addition shorten the diastolic filling of the heart, leading to a reduction in stroke volume; also, tachycardia may directly affect the level of arterial pressure. Heart rate is controlled by the efferent vagal drive (mainly at rest), sympathetic drive, angiotensin II and their interaction. Peripheral vascular resistance is also influenced by many factors, including the vasodilating and vasoconstricting effects of hormonal, neural and local factors. These factors are subject to complex interactions, 54, 55 though increases in cardiac output and vascular resistance are proposed to result from increased sympathetic drive. 55, 56 The cause of essential hypertension is not known, although findings in some patients have identified possibilities such as hereditary, race and genetic factors, environmental and demographic conditions, central nervous system functional and anatomical aberrations, vascular and neuroendocrine conditions. 54, 55, [57] [58] [59] [60] [61] [62] [63] These causes are subject to complex interactions. It is remarkable that many of these causes share the condition of sympathetic activation, in addition to their other effects. These include hormonal abnormalities and obesity, 64, 65 functional and anatomical changes in the brain 63, 66 and genetic factors. 67 
BP reduction
The relatively marked reduction in arterial BP afforded by renal artery ablation may prevent adverse atrial structural remodelling over and above the effect of single antihypertensive agents alone. Trials investigating the impact of antihypertensive medication in preventing AF recurrence have so far been largely negative, but the BP reduction seen in these studies was much more modest than that seen with renal artery ablation. 68, 69 The results of SMAC AF, an open-label, randomised control trial investigating the role of aggressive BP lowering following AF catheter ablation to reduce AF recurrence, may help to clarify some of these issues. 70 Effects of the RAS It is possible that renal artery ablation reduces the occurrence of AF via reduction in angiotensin II, leading to a regression of atrial fibrosis and possibly atrial inflammation. 71 In the absence of any data to currently support this theory, such statements remain hypothesis generating, although it is of interest that this theory is supported by the data suggesting that RAS inhibition with ACEis or angiotensin receptor blockers can contribute to a reduction in incidence of AF in certain groups. 15, 72 Direct reduction in sympathetic activity The associated reduction in sympathetic nervous system activation demonstrated with both muscle sympathetic nerve activity and noradrenaline spillover techniques may also have a part to play; 16, 73 the autonomic nervous system is involved in triggering of AF in the context of a vulnerable anatomical or electrophysiological substrate. Heart rate reduction has been reported in trials of renal artery ablation, suggesting an early and persistent effect on the sympathetic outflow to the heart. 50, 73 This physiological phenomenon is unique in that a reduction in heart rate accompanies a reduction in BP, suggesting a central resetting of autonomic baroreceptor-mediated reflex control of heart rate and BP. This will attract further investigation, but opens up new avenues when considering the therapeutic applications of renal artery ablation managing not only arrhythmia, but also heart failure, where a reduction in heart rate has been related to improved outcomes. 74 AF and the autonomic nervous system The autonomic nervous system has a complex relationship with the heart. The sympathovagal influence over the pathophysiology of atrial arrhythmia is well established. 75, 76 The heart is richly innervated with ganglionated plexi located primarily in the pulmonary vein left atrial junction, the great thoracic veins and the ligament of Marshall, 77 areas notorious as triggers of AF. Targeting these ganglionated plexi has been shown to improve outcomes following catheter ablation of AF. 78 It is unknown how any reduction in sympathetic nerve activation resulting from renal artery ablation may modulate the sympathovagal balance contributing to the initiation and perpetuation of AF, but this remains a postulated mechanism for the observed reduction in AF in the recently published trials.
Atrial remodelling Reduction in left ventricular mass and regression of left ventricular hypertrophy have been demonstrated following renal artery ablation. 17, 48 Such structural remodelling will improve indices of diastolic dysfunction, thereby potentially contributing to reversal of adverse atrial remodelling. This remains to be demonstrated, but could lead to hypotheses regarding which subgroups of AF patients might benefit from concomitant renal artery ablation.
PERSPECTIVE
The published work discussed above has shown promise in utilising a novel technique in addressing two important, interlinked and harmful cardiovascular pathologies. However, these considerations give rise to more questions: Can the findings of improved outcomes of AF ablation with concomitant ablation of the renal arteries be extrapolated to other patient groups with AF; those with more modest hypertension, or even without hypertension? Must patients have a prerequisite of high sympathetic drive and/or abnormal atrial structural and electrical remodelling in order to benefit, and if so, how are they identified? Can we take this so far as to suggest renal artery ablation alone as an interventional approach to AF, and if so, in which patients? 51 Finally, combining two ablation catheter-based interventional procedures into one will require close scrutiny with regard to patient safety, particular when considering increased procedure time, radiation exposure and the need for a relatively large catheter to be placed into the femoral artery in a fully anticoagulated patient undergoing AF ablation. These questions remain unanswered, and many more will be postulated, as this field continues to evolve. CONCLUSION AF is a common condition with significant morbidity, mortality and socioeconomic burden. It can be difficult to treat, especially in those with hypertension. Although the onset of AF can be delayed by the proper identification and treatment of patients with established hypertension, once established, novel ways of improving AF rhythm control must be sought. It seems that adding renal denervation to PVI ablation for AF could represent a safe option, with a low incremental cost, in treating patients with AF and resistant hypertension, especially as no further equipment or hardware is required. 79 At this stage, there are certainly more questions than answers, but this small but growing body of evidence opens the door for a potential new combined treatment strategy for patients with two of the most common cardiovascular conditions. It remains to be seen whether the outcomes continue to be favourable in patients with nonresistant hypertension, or whether the effect remains sustained over many years. Furthermore, identifying those likely to benefit remains far from established and, certainly, for the time being, the appropriateness of renal artery ablation to supplement AF ablation remains entirely uncertain. A large multicentre trial is currently in progress attempting to further define the role of renal artery ablation in the context of AF ablation. 80 The next few years will see much exciting scientific and clinical work in this field, reinvigorated by the results such as those described in this article. This new approach might also result in beneficial neurohormonal modifications for a number of important cardiovascular disease states that share sympathetic activation as a common pathological feature.
